Medical Therapy. Efficacy or Lack of Efficacy Archives - Page 13 of 42

Pediatric Use of Inhaled Iloprost

Stephanie S. Handler, Steven H. Abman, Nidhy P. Varghese, D. Dunbar Ivy Medical College of Wisconsin and Children’s WIsconsin. University of Colorado School of Medicine and Children’s Hospital Colorado. Baylor College of Medicine and Texas Children’s Hospital.United States Pulmonary CirculationPulm Circ 2025; 15: DOI: 10.1002/pul2.70115 AbstractAbstract Not Available CategoryMedical Therapy. Efficacy or Lack of Efficacy Age […]

Pediatric Use of Inhaled Iloprost Read More »

Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children with Sickle Cell Disease and Increased Tricuspid Regurgitant Jet Velocity: a Randomized Controlled Trial

Dalia A. Gomaa, Sahar M. El‑Haggar, Mohamed R. El‑Shanshory, Osama El‑Razaky, Dalia R. El‑AffyTanta University. Egypt Paediatric DrugsPaediatr Drugs 2025; DOI: 10.1007/s40272-025-00701-w AbstractBackground: Pulmonary hypertension (PH) is a common chronic complication of sickle cell disease (SCD), and patients at risk for PH can be identified by measuring tricuspid regurgitant jet velocity (TRJV). We looked for the possible

Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children with Sickle Cell Disease and Increased Tricuspid Regurgitant Jet Velocity: a Randomized Controlled Trial Read More »

Severe Early-Onset Pulmonary Hypertension in a Six-Month-Old With Down Syndrome and Isolated Secundum Atrial Septal Defect

Fatima Abeer, Aasim Ayaz Wani, Bisma Javid, Aisha Mahmood, Gazala AndleebGovernment Medical College, Srinagar. National Institute of Technology Srinagar. India CureusCureus 2025; 17: DOI: 10.7759/cureus.84019 AbstractInfants with Down syndrome (trisomy 21) commonly present with congenital heart defects and immune dysregulation, significantly increasing the risk of early-onset pulmonary arterial hypertension (PAH). Although secundum atrial septal defects (ASDs)

Severe Early-Onset Pulmonary Hypertension in a Six-Month-Old With Down Syndrome and Isolated Secundum Atrial Septal Defect Read More »

Evaluation of Treatment Effect of Sirolimus on Pediatric Pulmonary Vein Stenosis Using a Neonatal Rat Model

Debao Li, Yingying Xiao, Peisen Ruan, Zunmin Wan, Yuqing Hu, Sijuan Sun, Zheng Wang, Sixie Zheng, Yi Yan, Hao Chen, Hao Zhang, Chun Shen, Qi Sun, Lincai YeShanghai Children’s Medical Center and Shanghai Jiao Tong University School of Medicine. Children’s Hospital of Fudan University and National Children’s Medical Center. Women and Children’s Hospital of Ningbo

Evaluation of Treatment Effect of Sirolimus on Pediatric Pulmonary Vein Stenosis Using a Neonatal Rat Model Read More »

Juvenile Systemic Sclerosis Presenting With Severe Pulmonary Vascular Disease: ECMO Stabilization During Aggressive Therapy Resulting in a Favorable Outcome

Stephanie M. Tsoi, Shannon Cheung, Roberto Alejandro Valdovinos, Elena Amin, Hythem Nawaytou, Elizabeth Colglazier, Claire Parker, April Edwell, Susan Kim, Jeffrey R. FinemanUniversity of California San Francisco. Pulmonary CirculationPulm Circ 2025; 15: DOI: 10.1002/pul2.70106 AbstractJuvenile systemic sclerosis (jSSc) associated pulmonary hypertension (PH) is rare, but, the leading cause of morbidity and mortality in jSSc. This is

Juvenile Systemic Sclerosis Presenting With Severe Pulmonary Vascular Disease: ECMO Stabilization During Aggressive Therapy Resulting in a Favorable Outcome Read More »

Pulmonary artery-targeted low-dose metformin-loaded nanocapsules safely improve pulmonary arterial hypertension in rats

Ayako Chida-Nagai, Naoki Masaki, Hiroki Sato, Tatsuya Kato, Emi Takakuwa, Yoshihiro Matsuno, Atsushi Manabe, Atsuhito TakedaHokkaido University Hospital. Tokyo Women’s Medical University. Tohoku University Graduate School of Medicine. Oita University and Oita University Hospital.Japan Frontiers in PediatricsFront Pediatr 2025; 16: DOI: 10.3389/fphar.2025.1577570 AbstractIntroduction: Pulmonary arterial hypertension (PAH) remains a challenge to tackle despite various available medications. Metformin,

Pulmonary artery-targeted low-dose metformin-loaded nanocapsules safely improve pulmonary arterial hypertension in rats Read More »

MHCIIhiLYVE1loCCR2hi Interstitial Macrophages Promote Medial Fibrosis in Pulmonary Arterioles and Contribute to Pulmonary Hypertension

Fan Qiu, Hao-Ran Miao, Hong-Liang Hui, Lin-Jie Qiu, Yi Chen, Min Luo, Jian-Chao Zhang, Yan-Gui Lin, Dan Li, Sang-Bing Ong, Xue-Fei Hu, Bo Jiang, Yi-Qian ZhangEighth Affiliated Hospital of Sun Yat-sen University. Chinese University of Hong Kong. Hong Kong Children’s Hospital. China and Hong Kong Circulation ResearchCirc Res 2025; DOI: 10.1161/CIRCRESAHA.125.326173 AbstractBackground: Pulmonary hypertension (PH) is a

MHCIIhiLYVE1loCCR2hi Interstitial Macrophages Promote Medial Fibrosis in Pulmonary Arterioles and Contribute to Pulmonary Hypertension Read More »

Cyclopamine Attenuates Pulmonary Arterial Hypertension Development: Implications of Hedgehog Signaling Involvement for the Pathophysiology

Makito Sakurai, Susumu Hosakawa, Yohei Yamaguchi, Susumu Kirimura, Kensuke Ihara, Kenichi Ohashi, Tetsushi Furukawa, Tetsuo Sasano, Kenichi Kashimada, Taku IshiiInstitute of Science Tokyo. Japanese Red Cross Musashino Hospital. National Center for Child Health and Development. Japan Federation of American Societies for Experimental Biology JournalFASEB J 2025; 39: DOI: 10.1096/fj.202403350R AbstractPulmonary arterial hypertension (PAH) is one of

Cyclopamine Attenuates Pulmonary Arterial Hypertension Development: Implications of Hedgehog Signaling Involvement for the Pathophysiology Read More »

Role of phosphodiesterase-3 inhibitor in cardiorespiratory fitness and functional class of patients with pulmonary hypertension: A randomized, double-blind, placebo-controlled trial

Sefri N. Sofia, Udin Bahrudin, Ilham Uddin, Muhammad A. Sobirin, Erna Setiawati, Galuh Hardaningsih, Kevin C. Tjandra, Edward K. S. LimijadiUniversitas Diponegoro. Dr. Kariadi Hospital. Indonesia Narra JNarra J 2025; 5: DOI: 10.52225/narra.v5i1.1301 AbstractMany patients with acyanotic shunt congenital heart disease (CHD) are diagnosed only in adulthood, by which time pulmonary hypertension (PH) has developed, impairing

Role of phosphodiesterase-3 inhibitor in cardiorespiratory fitness and functional class of patients with pulmonary hypertension: A randomized, double-blind, placebo-controlled trial Read More »